Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Jun;21(6):939–943. doi: 10.1128/aac.21.6.939

Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

R K Scribner, M I Marks, A H Weber, M M Tarpay, D F Welch
PMCID: PMC182049  PMID: 6810757

Abstract

The inhibitory and bactericidal activities of carbenicillin, ticarcillin, moxalactam, cefoperazone, azlocillin, piperacillin, ceftazidime, and three aminoglycosides, alone and in various combinations, were determined against 60 isolates of Pseudomonas aeruginosa from the sputum of patients with cystic fibrosis. Ceftazidime was the most active beta-lactam, with minimum inhibitory and bactericidal concentrations for 90% of isolates of 4 micrograms/ml. Moxalactam was the least active of the new beta-lactams, with activity equivalent to that of carbenicillin; each had a minimum inhibitory concentration for 90% of isolates of 64 micrograms/ml and a minimum bactericidal concentration for 90% of isolates of 128 microgram/ml. All combinations of an aminoglycoside plus a beta-lactam showed favorable inhibitory effects. Combinations of beta-lactams showed mostly addition or indifference. Although little antagonism was seen with combinations of beta-lactams or with aminoglycoside-beta-lactam combinations, no consistent advantage of beta-lactam combinations was demonstrated in vitro. These results suggest several single drugs and combinations that merit clinical evaluation in cystic fibrosis patients with Pseudomonas pulmonary infections.

Full text

PDF
939

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander M. R., Berglund E. M., Kasik J. E., Fox A., Chinn W. M. The concentration of tobramycin in bronchial secretions. Chest. 1979 Jun;75(6):675–678. doi: 10.1378/chest.75.6.675. [DOI] [PubMed] [Google Scholar]
  2. Coppens L., Klastersky J. Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin. Antimicrob Agents Chemother. 1979 Mar;15(3):396–399. doi: 10.1128/aac.15.3.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dull W. L., Alexander M. R., Kasik J. E. Bronchial secretion levels of amikacin. Antimicrob Agents Chemother. 1979 Dec;16(6):767–771. doi: 10.1128/aac.16.6.767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Libke R. D., Clarke J. T., Ralph E. D., Luthy R. P., Kirby W. M. Ticarcillin vs carbenicillin: clinical pharmacokinetics. Clin Pharmacol Ther. 1975 Apr;17(4):441–446. doi: 10.1002/cpt1975174441. [DOI] [PubMed] [Google Scholar]
  5. Marks M. I., Hammerberg S., Greenstone G., Silver B. Activity of newer aminoglycosides and carbenicillin, alone and in combination, against gentamicin-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1976 Sep;10(3):399–401. doi: 10.1128/aac.10.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Marks M. I., Prentice R., Swarson R., Cotton E. K., Eickhoff T. C. Carbenicillin and gentamicin: pharmacologic studies in patients with cystic fibrosis and pseudomonas pulmonary infections. J Pediatr. 1971 Nov;79(5):822–828. doi: 10.1016/s0022-3476(71)80401-8. [DOI] [PubMed] [Google Scholar]
  7. Michalsen H., Bergan T. Azlocillin in respiratory tract infections with Pseudomonas aeruginosa in children with cystic fibrosis. Chemotherapy. 1980;26(2):135–140. doi: 10.1159/000237895. [DOI] [PubMed] [Google Scholar]
  8. O'Callaghan C. H., Acred P., Harper P. B., Ryan D. M., Kirby S. M., Harding S. M. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980 May;17(5):876–883. doi: 10.1128/aac.17.5.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Odio W., Van Laer E., Klastersky J. Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol. 1975 Jul;15(7):518–524. doi: 10.1002/j.1552-4604.1975.tb01474.x. [DOI] [PubMed] [Google Scholar]
  10. Parry M. F., Neu H. C., Merlino M., Gaerlan P. F., Ores C. N., Denning C. R. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr. 1977 Jan;90(1):144–148. doi: 10.1016/s0022-3476(77)80790-7. [DOI] [PubMed] [Google Scholar]
  11. Parsons J. N., Romano J. M., Levison M. E. Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers. Antimicrob Agents Chemother. 1980 Feb;17(2):226–228. doi: 10.1128/aac.17.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Prince A. S., Neu H. C. Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrob Agents Chemother. 1981 Oct;20(4):545–546. doi: 10.1128/aac.20.4.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Shah P. P., Briedis D. J., Robson H. G., Conterato J. P. In vitro activity of piperacillin compared with that of carbenicillin, ticarcillin, ampicillin, cephalothin, and cefamandole against Pseudomonas aeruginosa and Enterobacteriaceae. Antimicrob Agents Chemother. 1979 Mar;15(3):346–350. doi: 10.1128/aac.15.3.346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Weingärtner L., Sitka U., Patsch R., Richter I., Thiemann H. H. Zur Frage der Ausscheidung von Azlocillin in das Bronchialsekret im Kindesalter. Arzneimittelforschung. 1979;29(12A):1952–1954. [PubMed] [Google Scholar]
  15. Yu V. L., Vickers R. M., Zuravleff J. J. Comparative susceptibilities of Pseudomonas aeruginosa to 1-oxacephalosporin (LY 127935) and eight other antipseudomonal antimicrobial agents (old and new). Antimicrob Agents Chemother. 1980 Jan;17(1):96–98. doi: 10.1128/aac.17.1.96. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES